drugset / Trial / NCT02190695
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Phase 2
Completed
92 enrolled
Fox Chase Cancer Center
M.D. Anderson Cancer Center · collabTeva Pharmaceuticals USA · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Efficacy of each combination.
Timeline
- Start
- 2013-04-01
- Primary completion
- 2018-06-26
- Completion
- 2020-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Intravenous |